Company intelligence
Akelos Inc
Developing Opioid Alternatives for Treating Neuropathic Pain. Now Recruiting Accredited Investors - Invest.AkelosInc.com
About Akelos Inc
Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. The goal of Akelos is to address some of today’s most pressing areas of unmet needs. Over 21 million adults suffer from Neuropathic Pain in the US alone†, for which opioid medication is a common treatment. Associated costs exceed $90 billion/year in the US,† and roughly 40 ‐ 70% of people do not receive proper medical treatment and are at risk for either over‐ or under‐treatment.‡ Akelos: Building New Frontiers to Address Neuropathic Pain Akelos is an innovative research-based biotechnology company founded to address the Opioid epidemic through opioid alternatives, with two drug candidates in pre-clinical development. Akelos has proudly entered into a research collaboration to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. Akelos holds an exclusive worldwide license with Columbia University and Cornell University and is working in collaboration with Weill Cornell Medicine. Researchers at Weill Cornell University and Columbia University have developed novel compounds for the treatment of neuropathic pain, resulting in intellectual property that is jointly owned by Cornell and Columbia. Akelos has licensed this intellectual property and is developing a treatment for neuropathic pain using the novel compounds.
Verified activity
Signals from Akelos Inc
13 published signals
Research & Knowledge
Akelos Inc is testing a non opioid non addictive drug for chronic pain
Reported by Steven Fox DDS
Research & Knowledge
Akelos Inc is testing a non opioid non addictive drug for chronic pain that inhibits the HCN1 ion channel in the peripheral nervous system.
Reported by Steven Fox DDS
Capital & Finance
Akelos Inc is raising capital from accredited investors to continue FDA testing.
Reported by Steven Fox DDS
Research & Knowledge
Akelos Inc is testing a non opioid drug for chronic pain
Reported by Steven Fox DDS
Capital & Finance
Akelos Inc is raising capital to expand FDA testing
Reported by Steven Fox DDS
Research & Knowledge
Akelos Inc is testing a non opioid non addictive drug for chronic pain and raising capital to continue FDA testing.
Reported by Steven Fox DDS
Research & Knowledge
Akelos Inc is testing a non opioid non addictive drug for chronic pain.
Reported by Steven Fox DDS
Research & Knowledge
Akelos Inc is testing a non opioid non addictive drug for chronic pain.
Reported by Steven Fox DDS
Capital & Finance
Akelos Inc is raising capital from accredited investors to continue FDA testing for a non opioid non addictive drug for chronic pain.
Reported by Steven Fox DDS
Research & Knowledge
Akelos Inc is testing a non-opioid lead drug for chronic pain, inhibiting the HCN1 ion channel and raising capital from accredited investors.
Reported by Steven Fox DDS
Capital & Finance
Akelos Inc is fundraising to continue the development of AKE-1018 and to develop a second generation of peripheral HCN1 inverse agonists using SAR, molecular modeling, and AI techniques.
Reported by Steven Fox DDS
Research & Knowledge
Akelos Inc developed a proprietary series of peripherally restricted HCN1 selective inverse agonists to alleviate pain responses in a high bar rodent model of neuropathic pain.
Reported by Steven Fox DDS
Research & Knowledge
Akelos Inc is testing a non opioid non addictive drug for chronic pain.
Reported by Steven Fox DDS